CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. Issue 5 (5th February 2014)

• Record Type: Journal Article
• Authors: Mannelli, Francesco; Cutini, Ilaria; Gianfaldoni, Giacomo; Bencini, Sara; Scappini, Barbara; Pancani, Fabiana; Ponziani, Vanessa; Bonetti, Maria Ida; Biagiotti, Caterina; Longo, Giovanni; Bosi, Alberto
• Is Part Of: Cytometry. Volume 86:Issue 5(2014)
• Page Start: 340
• Page End: 349
• Publication Date: 2014-02-05
• Subjects: Flow cytometry -- Diagnostic use -- Periodicals; Cytodiagnosis -- Periodicals; 616.07582
• DOI: 10.1002/cyto.b.21156
• Languages: English
• ISSNs: 1552-4949

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cytob21156-sec-0001" sec-type="section"> <title>Background</title> <p>In acute myeloid leukemia (AML), CXCR4 expression has been correlated with leukocytosis and prognosis.</p> </sec> <sec id="cytob21156-sec-0002" sec-type="section"> <title>Methods</title> <p>We quantified CXCR4 expression by flow cytometry on leukemic cells in 142 AML patients.</p> </sec> <sec id="cytob21156-sec-0003" sec-type="section"> <title>Results</title> <p>We confirm a correlation between high CXCR4 expression and leukemic burden. Furthermore, we documented a correlation with platelet count, dysplastic megakaryopoiesis, hepato‐splenomegaly and extra‐hematological disease. NPM1‐mutated AML displayed a significantly higher intensity of CXCR4 compared to NPM1‐wt cases: it is conceivable its clinical phenotype to be driven by high CXCR4 expression.</p> </sec> <sec id="cytob21156-sec-0004" sec-type="section"> <title>Conclusions</title> <p>CXCR4 expression resulted in an independent prognostic factor. Our data support CXCR4 targeting as a potential therapeutic strategy. © 2014 International Clinical Cytometry Society</p> </sec> </abstract>